Core Viewpoint - Valiant Bio-B (09887) has seen a significant stock increase, rising over 6% and currently trading at 62.2 HKD, with a transaction volume of 24.4 million HKD, following the announcement of its core product, Valiantxin (LBL-024), receiving orphan drug designation from the European Commission for the treatment of extra-pulmonary neuroendocrine carcinoma (EP-NEC) [1] Group 1 - Valiantxin has reached an important milestone in its global development process, now in Phase II or registration clinical trials for three indications: non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and EP-NEC, demonstrating first-in-class (FIC) or best-in-class (BIC) potential [1] - On January 14, Valiantxin was granted Fast Track designation by the FDA for the treatment of extra-pulmonary neuroendocrine carcinoma, marking it as the first targeted therapy for the 4-1BB receptor to reach the registration clinical stage globally [1]
港股异动 | 维立志博-B(09887)再涨超6% 维利信获欧盟孤儿药资格及美国FDA快速通道资格认定